SERUM HBSAG LEVELS DURING PEGINTERFERON ALFA-2A TREATMENT IN HBEAG-POSITIVE CHRONIC HEPATITIS B: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL

被引：0
|
作者：
Kim, Bo Hyun [1 ,2 ]
Kim, Won [3 ]
Song, Fun Young [4 ]
Park, Myoung Hee [4 ]
Yoon, Jung-Hwan [5 ,6 ]
Lee, Youn Jae [7 ]
Park, Sung Jae [7 ]
Jung, Eun Uk [7 ]
Kim, Donghee [8 ]
Kim, Yoon Jun [5 ,6 ]
Lee, Hyo-Suk [5 ,6 ]
机构：
[1] Bundang Jesaeng Gen Hosp, Dept Internal Med, Songnam, South Korea
[2] Bundang Jesaeng Gen Hosp, Hepatol Ctr, Songnam, South Korea
[3] Seoul Metropolitan Govt Seoul Natl Univ Boramae M, Dept Internal Med, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea
[7] Inje Univ, Paik Hosp, Dept Internal Med, Pusan, South Korea
[8] Seoul Natl Univ Hosp, Gangnam Healthcare Ctr, Inst Healthcare Res, Seoul 110744, South Korea
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
390
引用
收藏
页码：514A / 514A
页数：1
相关论文
共 50 条
  • [21] EXTENDING THE TREATMENT DURATION OF PEGINTERFERON ALFA-2A THERAPY TO 72 WEEKS INCREASES THE RATE OF HBeAg SEROCONVERSION IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
    Zhu, Y. -Y.
    Dong, J.
    Chen, Y. -T.
    Chen, J.
    Jiang, J. -J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S331 - S332
  • [22] PREDICTION OF SUSTAINED RESPONSE TO PEGINTERFERON ALFA-2B FOR HBEAG-POSITIVE CHRONIC HEPATITIS B USING ON-TREATMENT HBSAG DECLINE
    Sonneveld, Milan J.
    Rijckborst, Vincent
    Boucher, Charles A.
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2010, 52 (04) : 530A - 530A
  • [23] New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAg-positive chronic hepatitis B
    Ning, Qin
    Han, Meifang
    Sun, Yongtao
    Jiang, Jia-ji
    Tan, Deming
    Hou, Jinlin
    Tang, Hong
    Sheng, Jifang
    Zhao, Mianzhi
    HEPATOLOGY, 2012, 56 : 300A - 301A
  • [24] IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B HBSAG SERUM LEVELS EARLY DURING TREATMENT WITH PEGINTERFERON ALFA-2A PREDICT HBSAG CLEARANCE 4 YEARS POST-TREATMENT
    Marcellin, Patrick
    Brunetto, Maurizia
    Bonino, Ferruccio
    Hadziyannis, Stephanos J.
    Kapprell, Hans-Peter
    McCloud, Philip I.
    Batrla, Richard
    HEPATOLOGY, 2008, 48 (04) : 718A - 719A
  • [25] ALT FLARES DURING TREATMENT WITH PEGINTERFERON LAMBDA OR PEGINTERFERON alfa IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B INFECTION (CHB)
    Chan, H. L.
    Ahn, S. H.
    Chang, T. -T.
    Peng, C. -Y.
    Wong, D.
    Coffin, C.
    Lim, S. G.
    Chen, P. -J.
    Janssen, H. L.
    Marcellin, P.
    Serfaty, L.
    Zeuzem, S.
    Hu, W.
    Critelli, L.
    Wind-Rotolo, M.
    Srinivasan, S.
    Lopez-Talavera, J. C.
    Cooney, E.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S300 - S300
  • [26] Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
    Hsu, Chao-Wei
    Su, Wei-Wen
    Lee, Chuan-Mo
    Peng, Cheng-Yuan
    Chuang, Wan-Long
    Kao, Jia-Horng
    Chu, Heng-Cheng
    Huang, Yi-Hsiang
    Chien, Rong-Nan
    Liaw, Yun-Fan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (07) : 588 - 597
  • [27] A novel baseline prediction model based on HBsAg levels predicts the probability of response to peginterferon alfa in HBeAg-positive chronic hepatitis B
    Sonneveld, Milan J.
    Chan, Henry Lik-Yuen
    Wong, Vincent W.
    Piratvisuth, Teerha
    Jia, Jidong
    Zeuzem, Stefan
    Gane, Edward J.
    Liaw, Yun -Fan
    Xie, Qing
    Janssen, Harry L.
    Hansen, Bettina E.
    HEPATOLOGY, 2013, 58 : 659A - 659A
  • [28] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [29] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-POSITIVE CHRONIC HEPATITIS B IN POLAND
    Jakubczyk, M.
    Paweska, J.
    Niewada, M.
    Berak, H.
    Szkultecka-Debek, M.
    Russel-Szymczyk, M.
    VALUE IN HEALTH, 2011, 14 (07) : A275 - A275
  • [30] Evidence for the efficacy of peginterferon alfa-2a (40 KD) (pegasys) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors
    Cooksley, WGE
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    JOURNAL OF HEPATOLOGY, 2002, 36 : 8 - 8
12345